librela
zoetis belgium - bedinvetmab - analgetikai - Šunys - for the alleviation of pain associated with osteoarthritis in dogs.
nexgard combo
boehringer ingelheim vetmedica gmbh - eprinomectin, esafoxolaner, praziquantel - eprinomectin, combinations, , avermectins, antiparasitic products, insecticides and repellents - katės - for cats with, or at risk from mixed infections by cestodes, nematodes and ectoparasites. veterinarinis vaistas yra tik nurodyta, kada visi trys grupes tuo pačiu metu.
daxocox
ecuphar nv - enflicoxib - priešgaisrinės ir antireumatinės priemonės - Šunys - for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.
solensia
zoetis belgium sa - frunevetmab - analgetikai - katės - for the alleviation of pain associated with osteoarthritis in cats.
cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemoraginiai - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.
femoston conti
viatris healthcare limited - estradiolis/didrogesteronas - plėvele dengtos tabletės - 0,5 mg/2,5 mg - dydrogesterone and estrogen
fibryga
octapharma (ip) sprl - Žmogaus fibrinogenas - milteliai ir tirpiklis injekciniam ar infuziniam tirpalui - 1 g - fibrinogen, human
venlafaxine portfarma
portfarma ehf. - venlafaksinas - pailginto atpalaidavimo kietosios kapsulės - 150 mg; 37,5 mg; 75 mg - venlafaxine
mifepristone linepharma
linepharma international limited - mifepristonas - tabletė - 200 mg - mifepristone
hemlibra
roche registration limited - emicizumab - hemofilija a - antihemoraginiai - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra gali būti naudojami visose amžiaus grupėse.